Jeil Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.82%

Jeil Pharmaceutical Co Ltd (271980) has an Asset Resilience Ratio of 0.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jeil Pharmaceutical Co Ltd (271980) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩4.11 Billion
≈ $2.79 Million USD Cash + Short-term Investments

Total Assets

₩501.66 Billion
≈ $339.97 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Jeil Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Jeil Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jeil Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 271980 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩4.11 Billion 0.82%
Total Liquid Assets ₩4.11 Billion 0.82%

Asset Resilience Insights

  • Limited Liquidity: Jeil Pharmaceutical Co Ltd maintains only 0.82% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jeil Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jeil Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Jeil Pharmaceutical Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Jeil Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.76% ₩3.98 Billion
≈ $2.70 Million
₩525.70 Billion
≈ $356.26 Million
+0.21pp
2023-12-31 0.55% ₩2.67 Billion
≈ $1.81 Million
₩487.33 Billion
≈ $330.25 Million
+0.52pp
2022-12-31 0.03% ₩142.46 Million
≈ $96.54K
₩456.89 Billion
≈ $309.63 Million
-0.45pp
2021-12-31 0.48% ₩2.04 Billion
≈ $1.38 Million
₩426.49 Billion
≈ $289.02 Million
-0.18pp
2020-12-31 0.66% ₩2.69 Billion
≈ $1.83 Million
₩409.66 Billion
≈ $277.62 Million
+0.66pp
2019-12-31 0.00% ₩4.76 Million
≈ $3.23K
₩401.59 Billion
≈ $272.15 Million
-0.09pp
2018-12-31 0.09% ₩350.00 Million
≈ $237.19K
₩402.90 Billion
≈ $273.04 Million
--
pp = percentage points

About Jeil Pharmaceutical Co Ltd

KO:271980 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$105.96 Million
₩156.35 Billion KRW
Market Cap Rank
#19059 Global
#917 in Korea
Share Price
₩10730.00
Change (1 day)
-1.01%
52-Week Range
₩9700.00 - ₩17390.00
All Time High
₩104611.38
About

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more